To validate and compare the functional consequences of HIF1α and HIF2α suppression in vivo, we utilized two AML patient‐derived xenograft (PDX) models from leukemia samples collected at diagnosis (Toffalori et al, 2019). This evidence concerns the gene EPAS1 and leukemia.